Cynosure (Nasdaq: CYNO), a developer and manufacturer of aesthetic treatment systems, and Hologic (Nasdaq: HOLX), a developer, manufacturer and supplier of diagnostics, medical imaging and surgical products, today announced the sale of Cynosure to Hologic in a transaction worth approximately $1.65 billion. The transaction is expected to close during late March or April of 2017.
The WilmerHale team on the transaction was led by Hal Leibowitz and Jason Kropp and included Andrew Bonnes, Kim Wethly, Leon Greenfield, Bruce Manheim, Steve Barrett, Laura Schneider, Amy Null, Julie Hogan Rodgers, Ciara Baker, Davis Sluis, Caroline Dotolo and Alex Civetta.
Read the press release for more information.